Novartis India Reports Strong Financial Performance in Q1 FY25

Novartis India, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ended June 2024. The company has shown a positive performance in this quarter, with its score improving from 4 to 15 in the last 3 months, according to MarketsMOJO.

One of the key factors contributing to this positive performance is the company’s operating cash flow, which has been consistently growing over the last three years and reached a high of Rs 113.40 crore annually. This indicates that the company has been able to generate higher cash revenues from its business operations.

Another positive aspect of the financial results is the quarterly profit before tax less other income (PBT), which has shown a growth of 51.60% year on year (YoY) and has a very positive trend in the near term. The net sales for the quarter also reached a high of Rs 92.29 crore, showing a positive trend in the near term.

Novartis India’s operating profit (PBDIT) for the quarter has also reached a high of Rs 23.97 crore, with a positive trend in the near term. This indicates that the company’s efficiency has improved. The operating profit margin for the quarter has also shown a positive trend, reaching a high of 25.97%.

The company’s profit before tax less other income (PBT) for the quarter has also reached a high of Rs 23.27 crore, with a positive trend in the near term. The profit after tax (PAT) for the quarter has also shown a growth of 27.0% YoY, with a positive trend in the near term.

In terms of liquidity, Novartis India has a strong position with cash and cash equivalents reaching a high of Rs 596.08 crore in the last six half yearly periods. This indicates that the company has a good short-term liquidity position.

Overall, Novartis India has shown a positive financial performance in the quarter ended June 2024, with various key indicators showing growth and improvement. This is a promising sign for the company and its investors.